1 Min Read
Dec 5 (Reuters) - 4SC AG:
* SIGNIFICANT MILESTONE REACHED FOR PIVOTAL RESMAIN STUDY OF RESMINOSTAT AS MAINTENANCE THERAPY IN CTCL
* TOP-LINE RESULTS EXPECTED IN FIRST HALF 2019 Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.